Microbicides in the prevention of HIV infection: Current status and future directions

Drugs

Volumn 70, Issue 10, 2010, Pages 1231-1243

  Nuttall, Jeremy ^a  

^a INTERNATIONAL PARTNERSHIP FOR MICROBICIDES   (United States)

Author keywords

biopolymers; C31G; carbomer polymer gel; HIV 1 entry inhibitors; HIV infections; maraviroc; nonoxinol 9; PC 515; prevention; PRO 2000; raltegravir; research and development; surfactants; tenofovir; therapeutic use

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ACIDFORM; ANTIRETROVIRUS AGENT; BMS 599793; CARBOPOL 974P; CARRAGEENAN; CELLULOSE SULFATE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYANOVIRIN N; DAPIVIRINE; ELVITEGRAVIR; ENFUVIRTIDE; HI 280; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IBALIZUMAB; INTEGRASE INHIBITOR; MARAVIROC; MIC 150; MICROBICIDE; MIV 150; MONOCLONAL ANTIBODY; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONOXINOL 9; POLYANION; PRO 2000; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAVVY; SURFACTANT; TENOFOVIR; TENOFOVIR DISOPROXIL; TIFUVIRTIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIVAGEL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NEW DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; CLINICAL ASSESSMENT; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNITY; DEVELOPING COUNTRY; DISEASE TRANSMISSION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; EDUCATION; EXERCISE; GENITAL SYSTEM DISEASE; HERPES VIRUS INFECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MONITORING; REVIEW; SAFETY; SEXUAL TRANSMISSION; SIDE EFFECT; VAGINA FLORA; VIRUS INHIBITION; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; DRUG DEVELOPMENT; FEMALE; HIV INFECTIONS; INTRAVAGINAL DRUG ADMINISTRATION; PROCEDURES;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADMINISTRATION, INTRAVAGINAL; ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; DEVELOPING COUNTRIES; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; FEMALE; HIV INFECTIONS; HUMANS;

EID: 77953841413     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/10898650-000000000-00000     Document Type: Review

References (88)

1. Centers for Disease Control. Pneumocystis pneumonia: Los Angeles. MMWR Morb Mortal Wkly Rep 1981; 30: 250-252
2. Centers for Disease Control. Kaposi's sarcoma and Pneu-mocystis pneumonia among homosexual men: New York City and California. MMWR Morb Mortal Wkly Rep 1981; 30: 306-308
3. Wain-Hobson S, VartanianJ, Henry M, et al. LAV revisited: origins of the early HIV-1 isolates from Institute Pasteur. Science 1991; 252: 961-965
4. Joint United Nations Programme on HIV/AIDS (UNAIDS). AIDS epidemic update. Geneva: UNAIDS 2009 Dec
5. Joint United Nations Programme on HIV/AIDS (UN-AIDS). Report on the Global AIDS epidemic. Geneva: UNAIDS 2008 Aug
6. Wortley RM, Fleming PL. AIDS in women in the United States: recent trends. JAMA 1997; 278 (11): 911-916
7. Centers for Disease Control. Update: barrier protection against HIV infection and other sexually transmitted diseases. MMWR Morb Mortal Wkly Rep 1993; 42: 589-597
8. Stone AB, Hitchcock PJ. Vaginal microbicides for prevent-ing sexual transmission of HIV. AIDS 1994; 8: S285-93
9. Elias CJ, Heise LL. Challenges for the development of female-controlled vaginal microbicides. AIDS 1994; 8 (1): 1-9
10. Elias CJ, Coggins C. Female-controlled methods to prevent sexual transmission of HIV. AIDS 1996; 10: S43-51
11. Joint United Nations Programme on HIV/AIDS (UN-AIDS). AIDS epidemic update. Special report on HIV prevention. Geneva: UNAIDS, 2005 Dec
12. Cohen SA. Beyond slogans: lessons from Uganda's experi-ence with ABC and HIV/AIDS. Guttmacher Rep Public Policy 2003; 6 (5): 1-3
13. Katz IT, Wright AA. Circumcision: a surgical strategy for HIV prevention in Africa. N Engl J Med 2008; 359 (23): 2412-2415
14. Combescure C, Vallier N, Ledergerber B, et al. How reliable is an undetectable viral load? HIV Med 2009; 10 (8): 470-476
15. Shattock RA, Moore JP. Inhibiting HIV-1 sexual transmis-sion. Nat Rev Microbiol 2003; 1: 25-34
16. Scordi-Bello IA, Mosoian A, He C, et al. Candidate sulfo-nated and sulfated topical microbicides: comparison of antihuman immunodeficiency virus activities and mechanisms of action. Antimicrob Agents Chemother 2005; 49 (9): 3607-3615
17. Balzarini J, Van Damme L. Intravaginal and intrarectal microbicides to prevent HIV infection. CMAJ 2005; 172 (4): 461-464
18. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised, controlled trial. Lancet 2002; 360: 962-964
19. Kreiss J, Ngugi E, Holmes K, et al. Efficacy of nonoxynol 9 contraceptive sponge use in preventing heterosexual acquisition of HIV in Nairobi prostitutes. JAMA 1992; 268 (4): 477-482
20. Roddy RE, Zekeng L, Ryan KA, et al. A controlled trial of nonoxynol 9 film to reduce male-to-female transmission of sexually transmitted diseases. N Engl J Med 1998; 339 (8): 504-510
21. Beer BE, Doncel GF, Krebs FC, et al. In vitro preclinical testing of nonoxynol-9 as potential anti-human immunodeficiency virus microbicide: a retrospective analysis of results from five laboratories. Antimicrob Agents Chemother 2006; 50 (2): 713-723
22. Feldblum PJ, Adeiga A, Bakare R, et al. SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized controlled trial in Nigeria. PLoS One 2008; 3 (1): e1474
23. Peterson L, Nanda K, Opoku BK, et al. SAVVY® (C31G) gel for prevention of HIV infection in women: a phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2007; 2 (12): e1312
24. Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372 (9654): 1977-1987
25. Abdool Karim S, Coletti A, Richardson B, et al. Safety and effectiveness of vaginal microbicides BufferGel and 0.5% PRO 2000/5 gel for the prevention of HIV infection in women: results of the HPTN 035 trial [abstract no. 48LB]. 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8-11; Montreal (QC)
26. Medical Research Council. HIV 'prevention' gel PRO 2000 proven ineffective [online]. Available from URL: http://www.mrc.ac.uk/Newspublications/ News/MRC006553 [Accessed 2009 Dec 17]
27. Van Damme L, Govinden R, Mirembe FM, et al. Lack of effectiveness of cellulose sulfate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008; 359 (5): 463-472
28. Rupp R, Rosenthal SL, Stanberry LR. VivaGel (SPL7013 Gel): a candidate dendrimer-microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine 2007; 2 (4): 561-566
29. Williams DL, Newman DR, Ballagh SA, et al. Phase I safety trial of two vaginal microbicide gels (Acidform or Buffer-Gel) used with a diaphragm compared to KY jelly used with a diaphragm. Sex Transm Dis 2007; 34 (12): 977-984
30. Page CP, Curtis MJ, Sutter MC, et al., editors. Integrated pharmacology. London: Mosby, 1997.
31. Rustomjee R, Abdool Karim Q, Abdool Karim SS, et al. Phase 1 trial of nonoxynol-9 film among sex workers in South Africa. AIDS 1999; 13 (12): 1511-1515
32. Wilkinson D, Ramjee G, Tholandi M, et al. Nonoxynol-9 for preventing vaginal acquisition of sexually transmitted infections by women from men. Cochrane Database Syst Rev 2002; (4): CD003939
33. Grant RM, Hamer D, Hope T, et al. Whither or wither mi-crobicides? Science 2008; 321: 532-534
34. Woolfson A, Malcolm R, Morrow R, et al. Intravaginal ring delivery of the reverse transcriptase inhibitor TMC120 as an HIV microbicide. Int J Pharm 2006; 325 (1-2): 82-89
35. Lin P-F, Blair W, Wang T, et al. A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding. Proc Natl Acad Sci USA 2003; 100 (19): 11013-11018
36. Veazey RS, Klasse PJ, Schader SM, et al. Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005; 438 (7064): 99-102
37. Mori T, Boyd MR. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrob Agents Chemother 2001; 45 (3): 664-672
38. Liu X, Lagenaur LA, Simpson DA, et al. Engineered vaginal Lactobacillus for mucosal delivery of the HIV inhibitor, Cyanovirin-N. Antimicrob Agents Chemother 2006; 50 (10): 3250-3259
39. Zeitlin L, Bohorova N, Hiatt A, et al. Preventing sexual transmission: MAPP66, a multi-purpose vaginal micro-bicide [abstract no. M-15]. Advancing Prevention Technologies for Sexual Reproductive Health: A Strategy Symposium; 2009 Mar 24-25; Berkeley (CA)
40. Jacobson JM, Kuritzkes DR, Godofsky E, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 2009; 53 (2): 450-457
41. US National Institutes of Health. A phase 2b, randomized, double-blinded, 48-week, multicenter, dose-response study of ibalizumab plus an optimized background regimen in treatment-experienced patients infected with HIV-1 [Clin-icalTrials.gov identifier NCT00784147]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2009 Oct 5]
42. Philpott SM. HIV-1 coreceptor usage, transmission, and disease progression. Curr HIV Res 2003; 1 (2): 217-227
43. Lieberman-Blum SS, Fung HB, Bandres JC. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 2008; 30 (7): 1228-1250
44. Veazey RS, Ling B, Green LC, et al. Topically applied re-combinant chemokine analogues fully protect macaques from vaginal simian-human immunodeficiency virus challenge. J Infect Dis 2009; 199: 1525-1527
45. Funf HB, Guo Y. Enfuvirtide: A fusion inhibitor for the treatment of HIV infection. Clin Ther 2004; 26 (3): 352-378
46. Veazey RS, Ketas TA, Klasse PJ, et al. Tropism-independent protection of macaques against vaginal transmission of three SHIVs by the HIV-1 fusion inhibitor T-1249. Proc Natl Acad Sci USA 2008; 105 (30): 10531-10536
47. Ingallinella P, Bianchi E, Ladwa NA, et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci USA 2009; 106 (14): 5801-5806
48. Sperling R. Zidovudine. Infect Dis Obstet Gynecol 1998; 6: 197-203
49. Lyseng-Williamson KA, Reynolds NA, Plosker GL. Teno-fovir disoproxil fumarate: a review of its use in the management of HIV infection. Drugs 2005; 65 (3): 413-432
50. Padian NS, Buve A, Balkus J, et al. Biomedical interventions to prevent HIV infection: evidence, challenges, and way forward. Lancet 2008; 372 (9638): 585-599
51. Grobler JA, Dornadula G, Rice MR, et al. HIV-1 reverse transcriptase plus-strand initiation exhibits preferential sensitivity to non-nucleoside reverse transcriptase inhibitors in vitro. J Biol Chem 2007; 282 (11): 8005-8010
52. 14C]dapivirine for 7 days. Antimicrob Agents Chemother 2008; 52 (3): 909-914
53. Fernandez-Romero JA, Thorn M, Turville SG, et al. Car-rageenan/MIV-150 (PC-815), a combination microbicide. Sex Transm Dis 2007; 34: 9-14
54. Van Herrewege Y, Michiels J, Van Roey J, et al. In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrob Agents Chemo-ther 2004; 48: 337-339
55. D'Cruz OJ, Uckun FM. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides. J Antimicrob Chemother 2006; 57 (3): 411-423
56. Di Santo R, Costi R, Artico M, et al. HIV-1 integrase in-hibitors that block HIV-1 replication in infected cells: planning synthetic derivatives from natural products. Pure Appl Chem 2003; 75 (2-3): 195-206
57. Serrao E, Odde S, Ramkumar K, et al. Raltegravir, elvite-gravir, and metoogravir: the birth of "me-too" HIV-1 integrase inhibitors [published erratum appears in Retro-virology 2009; 6: 33]. Retrovirology 2009; 6: 25
58. Robins T, Plattner J. HIV protease inhibitors: their anti-HIV activity and potential role in treatment. J Acquir Immune Defic Syndr 1993; 6 (2): 162-170
59. Haase AT. Perils at mucosal front lines for HIV and SIV and their hosts. Nat Rev Immunol 2005; 5 (10): 783-792
60. Vermund SH. Prevention of mother-to-child transmission of HIV in Africa. Top HIV Med 2004; 12 (5): 130-134
61. Portsmouth SD, Scott CJ. The renaissance of fixed dose combinations: Combivir. Ther Clin Risk Manag 2007; 3 (4): 579-583
62. Blower S, Bodine E, Kahn J, et al. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 2005; 19 (1): 1-14
63. Martinez J, Coplan P, Wainberg MA. Is HIV drug resistance a limiting factor in the development of anti-HIV NNRTI and NRTI-based vaginal microbicide strategies? Antiviral Res 2006; 71 (2-3): 343-350
64. Malcolm RK, Woolfson AD, Toner CF, et al. Long-term, controlled release of the HIV microbicide TMC120 from silicone elastomer vaginal rings. J Antimicrob Chemother 2005; 56 (5): 954-956
65. Van de Wijgert J, Jones H. Challenges in microbicide trial design and implementation. Stud Fam Plann 2006; 37 (2): 123-129
66. Garg AB, Nuttall J, Romano J. The future of HIV micro-bicides: challenges and opportunities. Antivir Chem Che-mother 2009; 19 (4): 143-150
67. Keller MJ, Zerhouni-Layachi B, Cheshenko N, et al. PRO 2000 gel inhibits HIV and herpes simplex virus infection following vaginal application: a double-blind placebo-controlled trial. J Infect Dis 2006; 193: 27-35
68. Keller MJ, Mesquita PMM, Torres NM, et al. Postcoital bioavailability and antiviral activity of 0.5% PRO 2000 gel: implications for future microbicide clinical trials. PLoS One 2010; 5 (1): e8781
69. Elliott J, McGowan I, Adler A, et al. Strong suppression of HIV-1 infection of colorectal explants following in vivo rectal application of UC781 gel: anovel endpoint in a phase I trial [abstract no. 1067]. 16th Conference on Retroviruses and Opportunistic Infections; 2009 Feb 8-11; Montreal (QC)
70. Wallace A, Mitchell T, Maguire R, et al. Assay for estab-lishing whether microbicide applicators have been exposed to the vagina. Sex Transm Dis 2004; 31: 465-468
71. Wallace AR, Teitelbaum A, Wan L, et al. Determining the feasibility of utilizing the microbicide applicator compliance assay for use in clinical trials. Contraception 2007; 76: 53-56
72. Metzger DS, Koblin B, Turner C, et al. Randomized con-trolled trial of audio computer-assisted self-interviewing: utility and acceptability in longitudinal studies. Am J Epidemiol 2000; 152 (2): 99-106
73. Mesquita PM, Cheshenko N, Wilson SS, et al. Disruption of tight junctions by cellulose sulfate facilitates HIV infection: model of microbicide safety. J Infect Dis 2009; 200 (4): 599-608
74. Keller MJ, Herold BC. Understanding basic mechanisms and optimizing assays to evaluate the efficacy of vaginal microbicides. Sex Transm Dis 2009; 36 (3 Suppl.): S92-5
75. Trifonova RT, Doncel GF, Fichorova RN. Polyanionic microbicides modify Toll-like receptor-mediated cervi-covaginal immune responses. Antimicrob Agents Che-mother 2009; 53 (4): 1490-1500
76. Wilson DP, Coplan PM, Wainberg MA, et al. The para-doxical effects of using antiretroviral-based microbicides to control HIV epidemics. Proc Natl Acad Sci USA 2008; 105 (28): 9835-9840
77. Miller V, de Bethune M-P, Kober A, et al. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother 1998; 42 (12): 3123-3129 (Pubitemid 28553729)
78. Orrell C, Harling G, Lawn SD, et al. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited. Antivir Ther 2007; 12: 83-88
79. Coplan PM, Mitchnick M, Rosenberg ZF. Regulatory chal-lenges in microbicide development. Science 2004; 304: 1911-1912
80. Milstien J, Belgharbi L. Regulatory pathways for vaccines for developing countries. Bull World Health Organ 2004; 82 (2): 128-133
81. Committee for Medicinal Products for Human Use (CHMP). Guideline on procedural aspects regarding a CHMP scientific opinion in the context of cooperation with the World Health Organisation (WHO) for the evaluation of medicinal products intended exclusively for markets outside the community. EMEA/CHMP/5579/04 Rev.1. London: CHMP, 2005
82. Collaborating with traditional healers for HIV prevention and care in sub-Saharan Africa: suggestions for programme managers and field workers. UNAIDS Best Practice Collection. Geneva: World Health Organization, 2006
83. van de Wijgert JHHM, Mason PR, Gwanzura L, et al. In-travaginal practices, vaginal flora disturbances, and acquisition of sexually transmitted diseases in Zimbabwean women. J Infect Dis 2000; 181: 587-594
84. Myer L, Kuhn L, Stein Z, et al. Intravaginal practices, bac-terial vaginosis, and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis 2005; 5 (12): 786-794
85. Baleta A. Concern voiced over "dry sex" practices in South Africa. Lancet 1998; 352: 1292
86. Bendavid E, Young SD, Katzenstein DA, et al. Cost-effec-tiveness of HIV monitoring strategies in resource-limited settings: a Southern African analysis. Arch Intern Med 2008; 168 (17): 1910-1918
87. Lagoy CT, Joshi N, Cragan JD, et al. Medication use during pregnancy and lactation: an urgent call for public health action. J Womens Health (Larchmt) 2005; 14 (2): 104-109
88. Moodley K. Microbicide research in developing countries: have we given the ethical concerns due consideration? BMC Med Ethics 2007; 8: 10